Literature DB >> 15778922

Pyrrolidon carboxypeptidase activities in the hypothalamus-pituitary-thyroid and hypothalamus-pituitary-ovary axes of rats with mammary gland cancer induced by N-methyl nitrosourea.

M P Carrera1, M J Ramírez-Expósito, M T Valenzuela, M J García, M D Mayas, J M Arias de Saavedra, R Sánchez, M C Pérez, J M Martínez-Martos.   

Abstract

Pyrrolidon carboxypeptidase is an omega-peptidase that hydrolyses N-terminal pyroglutamyl residues from biologically active peptides such as gonadotropin-releasing and thyrotrophin-releasing hormones. We previously described a decrease in both rat and human pyrrolidon carboxypeptidase activity with breast cancer, suggesting that gonadotropin-releasing hormone may be an important local intracrine, autocrine and/or paracrine hormonal factor in the pathogenesis of breast cancer while playing a role in the tumoral process. However, the other susceptible substrate of pyrrolidon carboxypeptidase, thyrotrophin-releasing hormone, may also be modified with breast cancer, supporting an association between breast cancer and thyroid disorders. The present work analyses soluble and membrane-bound pyrrolidon carboxypeptidase activities in the hypothalamus-pituitary-thyroid and hypothalamus-pituitary-ovary axes in N-methyl nitrosourea-induced breast cancer in rats. Our aim was to determine the possible relationship between gonadotropin-releasing hormone and thyrotrophin-releasing hormone regulation through pyrrolidon carboxypeptidase activity. We propose that pyrrolidon carboxypeptidase activity dysregulation at various local and systemic levels may participate in the initiation, promotion and progression of breast cancer induced in rat by N-methyl nitrosourea through the increase in gonadotropin-releasing hormone. Since pyrrolidon carboxypeptidase activity also acts on thyrotrophin-releasing hormone, the dysregulation of this enzyme's activity could indirectly affect hypothalamus-pituitary-thyroid axis function, and thus potentially represent a link between the diseases of thyroid and breast cancer.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15778922     DOI: 10.1055/s-2005-861158

Source DB:  PubMed          Journal:  Horm Metab Res        ISSN: 0018-5043            Impact factor:   2.936


  2 in total

1.  Hypothalamus-pituitary-thyroid axis disruption in rats with breast cancer is related to an altered endogenous oxytocin/insulin-regulated aminopeptidase (IRAP) system.

Authors:  María Pilar Carrera-González; María Jesús Ramírez-Expósito; Jose Manuel Arias de Saavedra; Rafael Sánchez-Agesta; María Dolores Mayas; Jose Manuel Martínez-Martos
Journal:  Tumour Biol       Date:  2011-01-05

2.  Breast cancer prognosis is better in patients who develop subsequent metachronous thyroid cancer.

Authors:  Kefeng Lei; Xujun He; Leibo Yu; Chao Ni; Hailong Chen; Dandan Guan; Kewang Sun; Hai Zou
Journal:  PLoS One       Date:  2019-05-01       Impact factor: 3.240

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.